Stimulating development of more and better paediatric cancer drugs will be key to making progress, particularly in some of the hardest-to-treat childhood cancers. Gilles Vassal, past-President of the European Society for Paediatric Oncology, outlines emerging strategies to make this happen.
Stimulating development of more and better paediatric cancer drugs will be key to making progress, particularly in some of the hardest-to-treat childhood cancers.
Gilles Vassal, past-President of the European Society for Paediatric Oncology, outlines emerging strategies to make this happen.
Note: Comments are for discussion and clarification only. For medical advice, please consult with a healthcare professional.
Be the first to share your thoughts!
Discover the transformative power of advocacy for cancer patients. This article explores how advocacy connects patients...
A cancer diagnosis raises questions your employer probably won't answer first: Can they dismiss you? Do you have to tell...
Discover the importance of World Cancer Day, observed every February 4th, in uniting global efforts to fight cancer. Lea...
